Aeterna Zentaris Announces Completion of Patient Recruitment for Phase 3 Trial with Perifosine in Refractory Advanced Colorectal Cancer

Aeterna Zentaris Inc. AEZS today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer. The trial, involving over 430 patients, is being conducted pursuant to a Special Protocol Assessment with the Food and Drug Administration and with Fast Track Designation. It is sponsored by Keryx Biopharmaceuticals, Inc.,, KERX, Aeterna Zentaris' licensee for perifosine in North America. Perifosine is a novel, potentially first-in-class, oral anticancer drug candidate that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway.